Microsoft Recommends Philips SpeechMike Premium Touch as the Successor to Nuance PowerMic
Speech Processing Solutions, global leader in professional dictation solutions under the Philips brand, today announced that the Philips SpeechMike Premium Touch has been officially recognized by Microsoft as the recommended successor to the soon-to-be-retired Nuance PowerMic series.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507643740/en/
The Philips SpeechMike Premium Touch.
As the only microphone recommended by Microsoft for PowerMic replacement, the Philips SpeechMike Premium Touch delivers seamless, plug-and-play compatibility with many Nuance speech recognition solutions, including Dragon Medical One, Dragon Professional Anywhere, Dragon Legal Anywhere, and some versions of PowerScribe offering medical, legal and business professionals a superior alternative for uninterrupted documentation workflows.
With an intuitive button layout mirroring the PowerMic, the Philips SpeechMike Premium Touch offers users a familiar, yet enhanced dictation experience to enable effortless transitions. Already in use by millions of medical, legal and business professionals worldwide, the Philips SpeechMike Premium Touch offers:
- Compatibility with Dragon Medical One, Dragon Professional Anywhere, Dragon Legal Anywhere, and some versions of PowerScribe, as well as other legacy software such as Dragon NaturallySpeaking, Dragon Medical Practice Edition, and Winscribe
- Pre-configured Dragon function keys for convenient speech recognition control
- Studio-quality microphone with noise reduction for unprecedented accuracy in speech recognition
- Ergonomic design and hygienic housing, ideal for long-shift use and clinical work environments
- Advanced touch sensor navigation replaces the need to switch to a mouse
“With the PowerMic now being retired in the coming weeks, organizations must move quickly to maintain continuity in documentation,” said Dr. Thomas Brauner, CEO at Speech Processing Solutions. “The Philips SpeechMike Premium Touch is delivering both familiarity and unprecedented quality in speech recognition accuracy. I am delighted to be able to offer the Philips SpeechMike – the leading and most widely used dictation microphone in the world – to all existing PowerMic users.”
The Philips SpeechMike Premium Touch is available now through professional distribution channels.
Speech Processing Solutions (SPS):
Speech Processing Solutions (SPS) is the global leader in AI-powered dictation and transcription solutions. Active in over 50 countries with more than 4 million users and a network of 1,000+ partners, SPS develops award-winning speech-to-text technologies and devices under the Philips brand. Headquartered in Vienna, Austria, SPS is globally active with offices in Australia, Canada, Belgium, France, Germany, the UK, and the US.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250507643740/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Novotech Analysis Highlights Rising Clinical Development Efforts for Obesity Treatments8.5.2025 14:05:00 CEST | Press release
Novotech, a leading global clinical research organization (CRO) and scientific advisory partner, has published a report analyzing recent trends in obesity-related clinical trials. The report shows that the number of these trials tripled between 2019 and 2024, reflecting increased research activity and broader range of potential therapeutic options for obesity treatments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508533322/en/ Obesity continues to represent a major global health challenge, affecting nearly 900 million adults worldwide and placing a substantial burden on healthcare systems and quality of life. Strongly linked to conditions such as type 2 diabetes, cardiovascular disease, musculoskeletal disorders, and certain cancers, obesity demands targeted and innovative therapeutic strategies. The report provides biotech and pharmaceutical companies that engage in obesity-related therapies a comprehensive analysis
Cognite Fuels Industrial AI Revolution with Inaugural Class of Cognite Fellows8.5.2025 13:19:00 CEST | Press release
Cognite, the global leader in industrial AI, today announced the appointment of Torgrim Aas, Jan Eivind Danielsen, and Thorkild Stray as the inaugural class of Cognite Fellows. This landmark initiative underscores Cognite's deepening commitment to empowering customers with cutting-edge industrial Data and AI solutions while simultaneously building enduring know-how and competencies. These exceptional individuals represent the vanguard of Industrial Data and AI innovation, driving the energy transition and championing responsible, scalable industrialization on a global scale—areas where Cognite continues to see increasing demand and deliver tangible results for its expanding customer base. Establishing the Cognite Fellows Program signifies the company's ongoing investment in top-tier talent and its dedication to fostering a vibrant expert community that directly benefits customers and partners. Cognite Founder Dr. John Markus Lervik emphasized the significant contributions of the Cognit
Syncron Unveils Next-Gen Partner Network to Power the Future of Aftermarket Services8.5.2025 13:00:00 CEST | Press release
New Syncron Partner Network empowers a dynamic global ecosystem of partners to drive mutual growth Expanded partner types deliver targeted capabilities and services to maximize customer value Syncron, a global leader in intelligent Service Lifecycle Management (SLM) solutions, today announced the launch of the Syncron Partner Network, an enhanced partner program designed to strengthen its global ecosystem. This initiative will enable partners to extend Syncron’s capabilities across services, sales, marketing, and product innovation—ultimately accelerating the transformation of aftermarket operations for customers worldwide. The Syncron Partner Network introduces a structured, value-driven framework that supports a broader range of partner engagement models, giving customers new ways to access tailored expertise and solutions that enhance the impact of their Syncron SLM investments. With a focus on collaboration, innovation, and mutual success, the program is set to increase partner con
LumiThera’s LIGHTSITE IIIB Extension Trial Topline Results Show Extended Vision Improvement in Dry AMD Subjects8.5.2025 12:43:00 CEST | Press release
LumiThera Inc., a medical device company offering photobiomodulation (PBM) treatment for ocular damage and disease, today announced the topline results from the LIGHTSITE IIIB Extension Trial, a prospective, open-label trial in dry (non-neovascular) age-related macular degeneration (AMD) subjects. The extension trial followed subjects that completed the pivotal LIGHTSITE III trial and resumed treatment for 13 months with the Valeda® Light Delivery System. Dry AMD is a leading cause of central vision loss in people over 55 in developed countries. Valeda is the first FDA-authorized treatment (November, 2024) to improve vision in dry AMD patients. In the pivotal U.S. LIGHTSITE III trial, Valeda met the primary endpoint and was shown to be safe and effective. Valeda demonstrated an improvement in best corrected visual acuity (BCVA) for 24 months of >5 letters or equivalent to one line improvement on the eye chart. “The LIGHTSITE IIIB Extension Trial results extend two-year pivotal trial vi
Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights8.5.2025 12:30:00 CEST | Press release
Highlights:6-week top-line data from Part A of COMP005 phase 3 trial in treatment resistant depression on track for late JunePhase 3 COMP006 in TRD on track for 26-week data second half of 2026Cash position of $260.1 million at March 31, 2025Conference call on May 8 at 8:00 am ET (1:00 pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2025 and provided an update on recent progress across its business. “We eagerly await the upcoming topline 6-week data readout, on track for late June, the first data from our pivotal phase 3 COMP360 program in treatment resistant depression.” said Kabir Nath, Chief Executive Officer. “Our continued progress reinforces Compass’ leadership in psychedelic therapy development, which we believe represents the next generation of mental health therapeutic options and can lead to significant value cr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom